If you're looking for an undervalued growth stock to buy right now, Pfizer (NYSE: PFE) is an investment that should be near ...

The following content has been reviewed by a licensed attorney. Depo-Provera, a widely used injectable contraceptive, has ...

The pharmaceutical giant's stock has severely lagged the broader market in 2024, falling 2.43% while the S&P 500 has surged ...

Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower ...

Pfizer Inc. failed to warn patients that its injectable contraceptive drug Depo-Provera can increase the risk of developing ...

Pfizer's earnings were better than investors and management had anticipated. Its financial projections and forecasting abilities recently came under fire. It also raised its annual guidance, which ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

Pfizer has beaten analyst estimate both top- and bottom line. The firm has also raised its full-year guidance. Read my ...

Pfizer reported an adjusted EPS of $1.06, exceeding estimates by over 72%. Revenue reached $17.7 billion, marking a 32% year ...

Pfizer has a well-diversified pipeline, with several late-stage assets to drive medium-term growth. Learn more about PFE ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Pfizer (PFE – Research Report) today. The company’s shares ...